These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 15356415)
1. Atypical antipsychotics and metabolic dysregulation: evaluating the risk/benefit equation and improving the standard of care. Nasrallah HA; Newcomer JW J Clin Psychopharmacol; 2004 Oct; 24(5 Suppl 1):S7-14. PubMed ID: 15356415 [TBL] [Abstract][Full Text] [Related]
2. The Atypical Antipsychotic Therapy and Metabolic Issues National Survey: practice patterns and knowledge of psychiatrists. Newcomer JW; Nasrallah HA; Loebel AD J Clin Psychopharmacol; 2004 Oct; 24(5 Suppl 1):S1-6. PubMed ID: 15356414 [TBL] [Abstract][Full Text] [Related]
3. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine. Krzystanek M; Krupka-Matuszczyk I Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416 [TBL] [Abstract][Full Text] [Related]
4. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. Newcomer JW CNS Drugs; 2005; 19 Suppl 1():1-93. PubMed ID: 15998156 [TBL] [Abstract][Full Text] [Related]
5. [Metabolic side effects of risperidone in early onset schizophrenia]. Goeb JL; Marco S; Duhamel A; Kechid G; Bordet R; Thomas P; Delion P; Jardri R Encephale; 2010 Jun; 36(3):242-52. PubMed ID: 20620267 [TBL] [Abstract][Full Text] [Related]
6. Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature. Vuk A; Kuzman MR; Baretic M; Osvatic MM Psychiatr Danub; 2017 Jun; 29(2):121-135. PubMed ID: 28636569 [TBL] [Abstract][Full Text] [Related]
7. Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics. Henderson DC; Cagliero E; Copeland PM; Louie PM; Borba CP; Fan X; Freudenreich O; Goff DC J Clin Psychiatry; 2007 Apr; 68(4):533-41. PubMed ID: 17474808 [TBL] [Abstract][Full Text] [Related]
9. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Toren P; Ratner S; Laor N; Weizman A Drug Saf; 2004; 27(14):1135-56. PubMed ID: 15554747 [TBL] [Abstract][Full Text] [Related]
10. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Leslie DL; Rosenheck RA Am J Psychiatry; 2004 Sep; 161(9):1709-11. PubMed ID: 15337666 [TBL] [Abstract][Full Text] [Related]
11. Atypical antipsychotic drugs: current issues of safety and efficacy in the management of schizophrenia. Vohora D Curr Opin Investig Drugs; 2007 Jul; 8(7):531-8. PubMed ID: 17659473 [TBL] [Abstract][Full Text] [Related]
12. Quetiapine versus other atypical antipsychotics for schizophrenia. Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315 [TBL] [Abstract][Full Text] [Related]
13. Factors in antipsychotic drug selection: tolerability considerations. Nasrallah HA CNS Spectr; 2003 Nov; 8(11 Suppl 2):23-5. PubMed ID: 14978455 [TBL] [Abstract][Full Text] [Related]
14. Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer? Dubois D Curr Opin Pediatr; 2005 Apr; 17(2):227-33. PubMed ID: 15800418 [TBL] [Abstract][Full Text] [Related]
15. Real-World Data on the Adverse Metabolic Effects of Second-Generation Antipsychotics and Their Potential Determinants in Adult Patients: A Systematic Review of Population-Based Studies. Bernardo M; Rico-Villademoros F; García-Rizo C; Rojo R; Gómez-Huelgas R Adv Ther; 2021 May; 38(5):2491-2512. PubMed ID: 33826090 [TBL] [Abstract][Full Text] [Related]
16. [Drug-induced diabetes mellitus: the exemple of atypical antipsychotics]. Scheen AJ; De Hert M Rev Med Liege; 2005; 60(5-6):455-60. PubMed ID: 16035311 [TBL] [Abstract][Full Text] [Related]
17. [Schizophrenia, diabetes mellitus and antipsychotics]. Gury C Encephale; 2004; 30(4):382-91. PubMed ID: 15538314 [TBL] [Abstract][Full Text] [Related]
18. Planning for the optimal design of studies to personalize antipsychotic prescriptions in the post-CATIE era: the clinical and pharmacoepidemiological data suggest that pursuing the pharmacogenetics of metabolic syndrome complications (hypertension, diabetes mellitus and hyperlipidemia) may be a reasonable strategy. de Leon J; Diaz FJ Schizophr Res; 2007 Nov; 96(1-3):185-97. PubMed ID: 17618085 [TBL] [Abstract][Full Text] [Related]
19. [Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation]. Llorca PM; Miadi-Fargier H; Lançon C; Jasso Mosqueda G; Casadebaig F; Philippe A; Guillon P; Mehnert A; Omnès LF; Chicoye A; Durand-Zaleski I Encephale; 2005; 31(2):235-46. PubMed ID: 15959450 [TBL] [Abstract][Full Text] [Related]
20. A review of real-world data on the effects of aripiprazole on weight and metabolic outcomes in adults. Citrome L; Kalsekar I; Baker RA; Hebden T Curr Med Res Opin; 2014 Aug; 30(8):1629-41. PubMed ID: 24666104 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]